Table 3.

Phase III trial weight loss efficacy of new weight loss drugs.

Drug	Trial	Particulars of trial	Duration	Dose	Weight loss	Reference	Licensed in EU?
Phentermine / topiramate	EQUIP	Uncomplicated obesity	56 weeks	3.75/23 mg	−5.1%	Allison et al. [2012]	No
				15/92 mg	−10.9%
	CONQUER	Obesity plus metabolic syndrome comorbidities	56 weeks	7.5/46	−7.8%	Gadde et al. [2011]
				15/92	−9.8%
	SEQUEL	See above	108 weeks	7.5/46	−9.3%	Garvey et al. [2012]
				15/92	−10.5%
Lorcaserin	BLOOM	Obesity with nondiabetes metabolic syndrome comorbidity	52 weeks	10 mg BD	−5.8%	Smith et al. [2010]	No
	BLOOM-DM	Obesity and T2DM	52 weeks	10 mg OD	−5.0%	O’Neill et al. [2011]
				10 mg BD	−4.5%
	BLOSSOM	Obesity with nondiabetes metabolic syndrome comorbidity	52 weeks	10 mg OD	−4.7%	Fidler et al. [2011]
				10 mg BD	−5.8%
Naltrexone / bupropion	COR-I	Obesity without diabetes	56 weeks	16/360 mg	−5.0%	Greenwayet al. [2010]	Yes
				32/360 mg	−6.1%
	COR-II	Obesity and nondiabetes metabolic syndrome comorbidity	56 weeks	32/360 mg	−6.4%	Apovianet al. [2013]
	COR-DM	Obesity and T2DM	56 weeks	32/360 mg	−5.0%	Hollanderet al. [2013]

T2DM, type 2 diabetes mellitus; OD, once daily; BD, twice daily.